Literature DB >> 16775462

Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy.

Peter C Harris1, Vicente E Torres.   

Abstract

PURPOSE OF REVIEW: Polycystic kidney diseases are a group of inherited disorders that result in tubular dilatation and/or the development of fluid-filled cysts in the kidney. Identification and analysis of the primary defective protein in many of these diseases are providing insights into a common pathogenesis to polycystic kidney disease. This review explores this pathogenesis and determines the role that this knowledge is playing in the development of potential therapies. RECENT
FINDINGS: Study of simple and syndromic forms of polycystic kidney disease has revealed that the defective proteins are localized to the primary cilia/basal body and that the pleiotropic phenotypes are often associated with defective ciliogenesis. Data indicating that the polycystins are involved in ciliary mechanosensation, and cellular changes in intracellular Ca and cAMP, have provided clues for possible therapeutic approaches that have proved highly effective in pre-clinical trials.
SUMMARY: Polycystic kidney diseases are associated with defects to proteins involved in developing functional, sensory cilia in the kidney. While the primary defects in these disorders cannot be corrected at present, downsteam cellular changes can be targeted. Potential therapeutic agents are now being tested in patients, moving polycystic kidney disease research into a new and exciting phase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775462     DOI: 10.1097/01.mnh.0000232888.65895.e7

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  14 in total

1.  Nephrocystin and ciliary defects not only in the kidney?

Authors:  Christian von Schnakenburg; Manfred Fliegauf; Heymut Omran
Journal:  Pediatr Nephrol       Date:  2007-02-20       Impact factor: 3.714

Review 2.  Fish and frogs: models for vertebrate cilia signaling.

Authors:  Oliver Wessely; Tomoko Obara
Journal:  Front Biosci       Date:  2008-01-01

3.  Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease.

Authors:  Murali K Yanda; Boyoung Cha; Cristina V Cebotaru; Liudmila Cebotaru
Journal:  J Biol Chem       Date:  2019-09-30       Impact factor: 5.157

4.  Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.

Authors:  Sergio A Gradilone; Tatyana V Masyuk; Bing Q Huang; Jesus M Banales; Guillermo L Lehmann; Brynn N Radtke; Angela Stroope; Anatoliy I Masyuk; Patrick L Splinter; Nicholas F LaRusso
Journal:  Gastroenterology       Date:  2010-04-14       Impact factor: 22.682

5.  Molecular Biomechanics: The Molecular Basis of How Forces Regulate Cellular Function.

Authors:  Gang Bao; Roger D Kamm; Wendy Thomas; Wonmuk Hwang; Daniel A Fletcher; Alan J Grodzinsky; Cheng Zhu; Mohammad R K Mofrad
Journal:  Mol Cell Biomech       Date:  2010-03-02

6.  Failure of epithelial tube maintenance causes hydrocephalus and renal cysts in Dlg5-/- mice.

Authors:  Tamilla Nechiporuk; Tania E Fernandez; Valeri Vasioukhin
Journal:  Dev Cell       Date:  2007-09       Impact factor: 12.270

7.  LRRC50, a conserved ciliary protein implicated in polycystic kidney disease.

Authors:  Ellen van Rooijen; Rachel H Giles; Emile E Voest; Carina van Rooijen; Stefan Schulte-Merker; Freek J van Eeden
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

8.  Determinants of renal volume in autosomal-dominant polycystic kidney disease.

Authors:  J J Grantham; L T Cook; V E Torres; J E Bost; A B Chapman; P C Harris; L M Guay-Woodford; K T Bae
Journal:  Kidney Int       Date:  2007-10-24       Impact factor: 10.612

Review 9.  Cholangiociliopathies: genetics, molecular mechanisms and potential therapies.

Authors:  Tatyana Masyuk; Anatoliy Masyuk; Nicholas LaRusso
Journal:  Curr Opin Gastroenterol       Date:  2009-05       Impact factor: 3.287

10.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Joost P H Drenth; Hedwig d'Agnolo; Niek F Casteleijn; Johan W de Fijter; Tom J Gevers; Peter Kappert; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Vicente E Torres; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2013-12-15       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.